PT948358E - Formulacoes de interferao liquidas e estaveis - Google Patents
Formulacoes de interferao liquidas e estaveisInfo
- Publication number
- PT948358E PT948358E PT97952621T PT97952621T PT948358E PT 948358 E PT948358 E PT 948358E PT 97952621 T PT97952621 T PT 97952621T PT 97952621 T PT97952621 T PT 97952621T PT 948358 E PT948358 E PT 948358E
- Authority
- PT
- Portugal
- Prior art keywords
- liquid
- interferon
- compositions
- formulations
- beta
- Prior art date
Links
- 239000007788 liquid Substances 0.000 title abstract 7
- 239000000203 mixture Substances 0.000 title abstract 6
- 102000014150 Interferons Human genes 0.000 abstract 3
- 108010050904 Interferons Proteins 0.000 abstract 3
- 229940079322 interferon Drugs 0.000 abstract 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- 102000003996 Interferon-beta Human genes 0.000 abstract 2
- 108090000467 Interferon-beta Proteins 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 229960001388 interferon-beta Drugs 0.000 abstract 2
- 239000004475 Arginine Substances 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 1
- 230000002378 acidificating effect Effects 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000001179 sorption measurement Methods 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3435396P | 1996-12-24 | 1996-12-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT948358E true PT948358E (pt) | 2004-10-29 |
Family
ID=21875893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT97952621T PT948358E (pt) | 1996-12-24 | 1997-12-23 | Formulacoes de interferao liquidas e estaveis |
Country Status (27)
| Country | Link |
|---|---|
| EP (1) | EP0948358B2 (enExample) |
| JP (5) | JP4878664B2 (enExample) |
| KR (2) | KR101042660B1 (enExample) |
| CN (2) | CN1733296B (enExample) |
| AT (1) | ATE270899T1 (enExample) |
| AU (1) | AU738362B2 (enExample) |
| BG (2) | BG65171B1 (enExample) |
| BR (1) | BR9714434A (enExample) |
| CA (1) | CA2275890C (enExample) |
| CZ (1) | CZ300636B6 (enExample) |
| DE (1) | DE69729880T3 (enExample) |
| DK (1) | DK0948358T4 (enExample) |
| EA (1) | EA002754B1 (enExample) |
| EE (2) | EE04223B1 (enExample) |
| ES (1) | ES2224290T5 (enExample) |
| HU (1) | HU224222B1 (enExample) |
| IL (1) | IL130524A (enExample) |
| IS (1) | IS2070B (enExample) |
| MX (1) | MX337876B (enExample) |
| NO (1) | NO327844B1 (enExample) |
| NZ (2) | NZ336548A (enExample) |
| PL (1) | PL193447B1 (enExample) |
| PT (1) | PT948358E (enExample) |
| SI (1) | SI0948358T2 (enExample) |
| SK (1) | SK284989B6 (enExample) |
| TR (1) | TR199901968T2 (enExample) |
| WO (1) | WO1998028007A1 (enExample) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030190307A1 (en) | 1996-12-24 | 2003-10-09 | Biogen, Inc. | Stable liquid interferon formulations |
| SK284989B6 (sk) * | 1996-12-24 | 2006-04-06 | Biogen, Inc. | Kvapalná kompozícia obsahujúca interferón a spôsob stabilizácie interferónu |
| ES2181281T5 (es) * | 1997-09-23 | 2008-04-16 | Rentschler Biotechnologie Gmbh | Formulaciones liquidas de interferon beta. |
| KR100767473B1 (ko) * | 1999-05-31 | 2007-10-17 | 미쯔비시 가가꾸 가부시끼가이샤 | 간실질세포 증식인자 동결건조 제제 |
| US6887462B2 (en) * | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
| AR034749A1 (es) * | 2001-07-09 | 2004-03-17 | Schering Ag | Formulaciones de interferon beta humano |
| AU2002351756A1 (en) | 2001-12-21 | 2003-07-15 | Novo Nordisk Health Care Ag | Liquid composition of factor vii polypeptides |
| JP4340540B2 (ja) * | 2002-01-18 | 2009-10-07 | 旭化成ファーマ株式会社 | 可溶性トロンボモジュリン高濃度含有製剤 |
| AU2003240438A1 (en) | 2002-06-21 | 2004-01-06 | Novo Nordisk A/S | Stabilised solid compositions of factor vii polypeptides |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US7897734B2 (en) | 2003-03-26 | 2011-03-01 | Novo Nordisk Healthcare Ag | Method for the production of proteins |
| TWI272948B (en) | 2003-05-01 | 2007-02-11 | Ares Trading Sa | HSA-free stabilized interferon liquid formulations |
| AR044302A1 (es) * | 2003-05-13 | 2005-09-07 | Ares Trading Sa | Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos |
| BRPI0409936A (pt) | 2003-05-23 | 2006-04-25 | Novo Nordisk Healthcare Ag | uso de um material, recipiente pelo menos parcialmente cheio, e, kit médico |
| CN1318087C (zh) * | 2003-06-06 | 2007-05-30 | 北京三诺佳邑生物技术有限责任公司 | 去白蛋白神经生长因子制剂 |
| CA2534028A1 (en) | 2003-08-14 | 2005-02-24 | Novo Nordisk Health Care Ag | Liquid, aqueous pharmaceutical composition of factor vii polypeptides |
| MXPA06005510A (es) * | 2003-11-13 | 2006-12-14 | Johnson & Johnson | Composicion y aparato para distribucion transdermica. |
| EP1532983A1 (en) * | 2003-11-18 | 2005-05-25 | ZLB Bioplasma AG | Immunoglobulin preparations having increased stability |
| KR20130026498A (ko) | 2003-12-19 | 2013-03-13 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 인자 ｖｉｉ 폴리펩티드의 안정화된 조성물 |
| JP2008500995A (ja) * | 2004-06-01 | 2008-01-17 | アレス トレーディング ソシエテ アノニム | タンパク質安定化法 |
| JP4951344B2 (ja) * | 2004-08-24 | 2012-06-13 | 第一三共株式会社 | 生理活性ペプチド液状製剤 |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| US7595040B2 (en) * | 2004-11-10 | 2009-09-29 | Novartis Vaccines And Diagnostics, Inc. | Deamidated interferon-β |
| WO2006076453A2 (en) | 2005-01-12 | 2006-07-20 | Biogen Idec Ma Inc. | METHOD FOR DELIVERING INTERFERON-β |
| US20060188555A1 (en) * | 2005-01-21 | 2006-08-24 | Micheal Cormier | Therapeutic peptide formulations with improved stability |
| US20090148406A1 (en) | 2005-07-02 | 2009-06-11 | Arecor Limited | Stable Aqueous Systems Comprising Proteins |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| SG174054A1 (en) | 2006-05-04 | 2011-09-29 | Boehringer Ingelheim Int | Polymorphs |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| LT2868315T (lt) * | 2007-12-04 | 2017-09-25 | Biogen Chesapeake Llc | Patobulintos kompozicijos ir liofilizacijos būdai bei gauti liofilizatai |
| ATE555812T1 (de) | 2007-12-20 | 2012-05-15 | Merck Serono Sa | Peg-interferon-beta-formulierungen |
| PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| CN102066401A (zh) | 2008-05-01 | 2011-05-18 | 艾瑞克有限公司 | 蛋白质制品 |
| EP2328607A1 (en) | 2008-07-16 | 2011-06-08 | Arecor Limited | Stable formulation of a therapeutic protein |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
| RU2011113823A (ru) | 2008-09-10 | 2012-10-20 | БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) | Комбинированная терапия, предназначенная для лечения диабета и связанных с ним состояний |
| DE102008051574A1 (de) | 2008-10-14 | 2010-04-15 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Verfahren zur Herstellung von Interferon-beta und deren Varianten |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| EP2382216A1 (en) | 2008-12-23 | 2011-11-02 | Boehringer Ingelheim International GmbH | Salt forms of organic compound |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| DE102009032179A1 (de) | 2009-07-07 | 2011-01-13 | Biogenerix Ag | Verfahren zur Reinigung von Interferon beta |
| EP3646859A1 (en) | 2009-11-27 | 2020-05-06 | Boehringer Ingelheim International GmbH | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
| DK2531218T3 (en) | 2010-02-04 | 2019-04-01 | Csl Behring Ag | immunoglobulin |
| EP2361636A1 (en) | 2010-02-26 | 2011-08-31 | CSL Behring AG | Immunoglobulin preparation and storage system for an immunoglobulin preparation |
| DE102010011430A1 (de) * | 2010-03-15 | 2011-09-15 | Kurt Koch | Verfahren für den Bau des Nullenergiehauses in Schalenbauweise durch Ausschäumen aller Wände, Decken und Bedachung |
| NZ602921A (en) | 2010-05-05 | 2016-01-29 | Boehringer Ingelheim Int | Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor |
| KR20230051307A (ko) | 2010-06-24 | 2023-04-17 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| US9452216B2 (en) | 2010-12-09 | 2016-09-27 | Maruishi Pharmaceutical Co., Ltd. | Agent for stabilizing acetaminophen |
| JP6279905B2 (ja) | 2011-03-15 | 2018-02-14 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | 速い用量調節の漸増投与レジメンを用いた、インターフェロンの筋肉内投与に伴うインフルエンザ様症状を軽減するための方法 |
| AU2012285904C1 (en) | 2011-07-15 | 2017-08-31 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| MX2014012461A (es) * | 2012-04-19 | 2015-01-12 | Bard Inc C R | Soluciones intravenosas con estabilidad de ph mejorada bajo esterilizacion con oxido de etileno. |
| EP4151218A1 (en) | 2012-05-14 | 2023-03-22 | Boehringer Ingelheim International GmbH | Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis |
| US20130303462A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| ITMI20120913A1 (it) | 2012-05-28 | 2013-11-29 | Nicoletta Maxia | Uso della n-acetil-5-metossitriptamina o suoi analoghi per favorire il meccanismo di impianto dell' embrione, e relative composizioni e mezzi di coltura |
| CN103143000B (zh) * | 2013-03-07 | 2014-11-05 | 安徽安科生物工程（集团）股份有限公司 | 一种重组人干扰素α2b制剂 |
| EP3110449B1 (en) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
| JP2014208669A (ja) * | 2014-06-17 | 2014-11-06 | 株式会社スリー・ディー・マトリックス | タンパク質の凝集抑制剤 |
| JP6726666B2 (ja) | 2014-12-03 | 2020-07-22 | ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト | 免疫グロブリンを含む安定性が高められた医薬製品 |
| EP3468562A1 (en) | 2016-06-10 | 2019-04-17 | Boehringer Ingelheim International GmbH | Combinations of linagliptin and metformin |
| KR101943160B1 (ko) | 2016-10-06 | 2019-01-30 | 에이비온 주식회사 | 인터페론 베타 변이체의 안정화 제제 |
| SMT202300129T1 (it) | 2017-08-22 | 2023-05-12 | Biogen Ma Inc | Composizioni farmaceutiche contenenti anticorpi anti-beta amiloide |
| KR102731889B1 (ko) * | 2019-07-18 | 2024-11-19 | 에이비온 주식회사 | 2당화된 인터페론-베타 단백질의 정제 방법 |
| CN110714051B (zh) * | 2019-11-20 | 2023-04-07 | 迈克生物股份有限公司 | 蛋白c活性测定试剂盒 |
| CN115989239A (zh) * | 2020-04-29 | 2023-04-18 | 瑷备恩有限公司 | 具有双重突变的人干扰素β变体和用于改善人干扰素β变体的稳定性的方法 |
| EP4400432A3 (en) * | 2021-03-30 | 2024-09-18 | SCHOTT Pharma Schweiz AG | System for low-temperature storage of a pharmaceutical composi-tion, liquid composition, method and uses |
| CN114177273B (zh) * | 2021-11-29 | 2024-05-28 | 苏州人本药业有限公司 | 一种含有神经毒素的液体制剂及其制备方法 |
| KR20240150426A (ko) * | 2021-12-27 | 2024-10-15 | 에날레어 테라퓨틱스 인크. | 비경구 호흡 자극제 제형 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57175125A (en) * | 1981-04-20 | 1982-10-28 | Wakunaga Yakuhin Kk | Preparation of beta-interferon |
| EP0082481B2 (en) * | 1981-12-23 | 1990-09-12 | Schering Corporation | Stabilised alpha-interferon formulations and their preparation |
| JPS60243028A (ja) * | 1984-04-28 | 1985-12-03 | Kyowa Hakko Kogyo Co Ltd | インタ−フエロンの可溶化方法 |
| JPS63196268A (ja) * | 1987-02-10 | 1988-08-15 | Kanegafuchi Chem Ind Co Ltd | 無血清培地で継代増殖可能な形質転換細胞、その育種方法およびその細胞による蛋白質の生産方法 |
| EP0284249A1 (en) * | 1987-03-13 | 1988-09-28 | Interferon Sciences, Inc. | Lyophilized lymphokine composition |
| DE3729863A1 (de) * | 1987-09-05 | 1989-03-16 | Boehringer Mannheim Gmbh | Stabilisierte erythropoietin-lyophilisate |
| US4895716A (en) * | 1987-06-09 | 1990-01-23 | Biogen, Inc. | Stabilized formulations of gamma interferons |
| JPH02124832A (ja) * | 1988-07-08 | 1990-05-14 | Toray Ind Inc | インターヘェロンβ組成物 |
| DE3939346A1 (de) * | 1989-11-29 | 1991-06-06 | Behringwerke Ag | Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide |
| IL109350A (en) * | 1993-05-12 | 2001-01-28 | Genentech Inc | Stable liquid compositions of gamma interferon |
| TW249202B (enExample) * | 1993-08-13 | 1995-06-11 | Ciba Gerigy Corp | |
| US5545723A (en) * | 1994-03-15 | 1996-08-13 | Biogen Inc. | Muteins of IFN-β |
| JPH09511745A (ja) * | 1994-04-08 | 1997-11-25 | ブリガム アンド ウィミンズ ホスピタル | 経口寛容および／またはタイプｉインターフェロンを用いた自己免疫疾患の治療 |
| IT1272252B (it) * | 1994-05-16 | 1997-06-16 | Applied Research Systems | Formulazioni liquide di interferone beta |
| TW426523B (en) * | 1995-04-06 | 2001-03-21 | Hoffmann La Roche | Interferon solution |
| SK284989B6 (sk) * | 1996-12-24 | 2006-04-06 | Biogen, Inc. | Kvapalná kompozícia obsahujúca interferón a spôsob stabilizácie interferónu |
-
1997
- 1997-12-23 SK SK858-99A patent/SK284989B6/sk not_active IP Right Cessation
- 1997-12-23 CZ CZ0228299A patent/CZ300636B6/cs not_active IP Right Cessation
- 1997-12-23 EP EP97952621A patent/EP0948358B2/en not_active Expired - Lifetime
- 1997-12-23 EA EA199900597A patent/EA002754B1/ru not_active IP Right Cessation
- 1997-12-23 SI SI9730670T patent/SI0948358T2/sl unknown
- 1997-12-23 KR KR1020077010020A patent/KR101042660B1/ko not_active Expired - Lifetime
- 1997-12-23 DE DE69729880T patent/DE69729880T3/de not_active Expired - Lifetime
- 1997-12-23 DK DK97952621.7T patent/DK0948358T4/da active
- 1997-12-23 PL PL97334365A patent/PL193447B1/pl unknown
- 1997-12-23 EE EEP199900313A patent/EE04223B1/xx unknown
- 1997-12-23 WO PCT/US1997/023817 patent/WO1998028007A1/en not_active Ceased
- 1997-12-23 ES ES97952621T patent/ES2224290T5/es not_active Expired - Lifetime
- 1997-12-23 IL IL13052497A patent/IL130524A/xx not_active IP Right Cessation
- 1997-12-23 PT PT97952621T patent/PT948358E/pt unknown
- 1997-12-23 CN CN2005100915177A patent/CN1733296B/zh not_active Expired - Lifetime
- 1997-12-23 AT AT97952621T patent/ATE270899T1/de active
- 1997-12-23 AU AU56191/98A patent/AU738362B2/en not_active Expired
- 1997-12-23 TR TR1999/01968T patent/TR199901968T2/xx unknown
- 1997-12-23 BR BR9714434-7A patent/BR9714434A/pt active Search and Examination
- 1997-12-23 HU HU0000829A patent/HU224222B1/hu active IP Right Grant
- 1997-12-23 CN CNB971814996A patent/CN1222315C/zh not_active Expired - Lifetime
- 1997-12-23 JP JP52905698A patent/JP4878664B2/ja not_active Expired - Fee Related
- 1997-12-23 KR KR1019997005701A patent/KR20000069664A/ko not_active Ceased
- 1997-12-23 EE EEP200300127A patent/EE04266B1/xx unknown
- 1997-12-23 CA CA2275890A patent/CA2275890C/en not_active Expired - Lifetime
- 1997-12-23 NZ NZ336548A patent/NZ336548A/en not_active IP Right Cessation
-
1999
- 1999-06-21 IS IS5087A patent/IS2070B/xx unknown
- 1999-06-23 MX MX2012000515A patent/MX337876B/es unknown
- 1999-06-23 NO NO993121A patent/NO327844B1/no not_active IP Right Cessation
- 1999-07-19 BG BG103594A patent/BG65171B1/bg unknown
- 1999-07-19 BG BG109523A patent/BG65418B1/bg unknown
-
2001
- 2001-07-05 NZ NZ512792A patent/NZ512792A/xx not_active IP Right Cessation
-
2007
- 2007-05-18 JP JP2007133540A patent/JP2007204501A/ja not_active Withdrawn
-
2011
- 2011-01-07 JP JP2011002557A patent/JP5851695B2/ja not_active Expired - Lifetime
- 2011-10-04 JP JP2011220534A patent/JP2012006979A/ja not_active Withdrawn
-
2014
- 2014-02-25 JP JP2014033581A patent/JP2014098029A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT948358E (pt) | Formulacoes de interferao liquidas e estaveis | |
| CA2113995A1 (en) | Use of gentisic acid or gentisyl alcohol for stabilising radiolabeled peptides and proteins | |
| CA2032499A1 (en) | Polypeptide derivatives | |
| AU586892B2 (en) | Pharmaceutical and dietary composition | |
| GR3019901T3 (en) | Osteoinductive pharmaceutical formulations | |
| IE811275L (en) | Vinblastines | |
| PT662827E (pt) | Metodos de diagnostico e composicoes farmaceuticas a base de proteinas notch e acidos nucleicos | |
| AU1094892A (en) | Improved activation of recombinant proteins | |
| TW364850B (en) | Nematocidal compositions | |
| AU678421B2 (en) | Highly concentrated TCF pharmaceutical preparations | |
| AU3494093A (en) | S-lipophilic aliphatic carbonyl {n-mercaptoacyl-(amino acid or peptide)} compounds as antihypertensive agents | |
| EP0063328A3 (en) | Compositions containing secretin and method for preventing the adsorption of secretin | |
| EP0508435A3 (en) | Pharmaceutical composition of stabilized (leu 13)-motilin-hse | |
| Sebald et al. | Cooperation of mitochondrial and cytoplasmic protein synthesis in the formation of cytochrome c oxidase | |
| KR860003012A (ko) | (-)시스-1,2-에폭시프로필포스폰산과 아미노산과의 염을 함유하는 수용성 제약 조성물 |